Standard treatments for brain and spinal cord tumors, like chemotherapy and surgery, often fall short due to their difficult access and aggressive nature. Dr. Jay Read, a clinical assistant professor of pediatrics and pediatric hematology-oncology, is leading the way with a groundbreaking new therapy—Chimeric Antigen Receptor (CAR) T-cell therapy. With Phase I trials now underway, U-M is exploring how this innovative treatment could offer hope for patients with inoperable brain tumors. Read on to discover how this cutting-edge approach could change the future of cancer treatment.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.